Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial
about
Recent advances in anti-neutrophil cytoplasmic antibody-associated vasculitisSpotlight on rituximab in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: current perspectivesTherapeutic plasma exchange and renal related vasculitis: therapeutic apheresis academy 2010.The potential utility of B cell-directed biologic therapy in autoimmune diseases.Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders.Diabetes insipidus as a complication of Wegener's granulomatosis and its treatment with biologic agents.The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease.B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients.Efficacy of remission-induction regimens for ANCA-associated vasculitis.Advances in the use of biologic agents for the treatment of systemic vasculitisRituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitisMalignancy in systemic lupus erythematosus: what have we learned?Diagnosis and treatment of cerebral vasculitis.Rheumatoid vasculitis: vanishing menace or target for new treatments?Successful Treatment of ANCA-Negative Wegener's Granulomatosis with Rituximab.Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides.Rituximab for non-Hodgkin's lymphoma: a story of rapid success in translation.Challenges in the pursuit of immune tolerance.Rheumatoid arthritis-associated interstitial lung disease: diagnostic dilemmaCurrent therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximabRituximab versus cyclophosphamide for ANCA-associated vasculitis.Combination therapy with rituximab and cyclophosphamide in the treatment of anti-neutrophil cytoplasmic antibodies (ANCA) positive pulmonary hemorrhage: case report.Rituximab for the treatment of Churg-Strauss syndrome with renal involvement.Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID).Incidence of Cancer in ANCA-Associated Vasculitis: A Meta-Analysis of Observational Studies.Development of comprehensive disease assessment in systemic vasculitis.Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system.Pro: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab?Low immunoglobulin levels increase the risk of severe hypogammaglobulinemia in granulomatosis with polyangiitis patients receiving rituximab.Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamideUpdated consensus statement on biological agents for the treatment of rheumatic diseases, 2007Update on diffuse alveolar hemorrhage and pulmonary vasculitis.Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.Indomethacin-related leukocytoclastic vasculitis: a case report and review of literature.Update in diffuse parenchymal lung disease 2006.ANCA-associated vasculitis: new options beyond steroids and cytotoxic drugs.Refractory Granulomatosis with Polyangiitis Presenting as Facial Paralysis and Bilateral Sudden DeafnessB cell modulation in rheumatologyB-cell depletion with rituximab in the treatment of autoimmune diseases. Graves' ophthalmopathy the latest addition to an expanding family.
P2860
Q26751357-5FB59254-4E6A-471B-A225-4873DBAC769DQ26776308-F77CB429-2889-4827-91DA-F0F81A690E04Q30454083-B22EF3F6-F1A7-4FFF-BFED-F25BBBD0B651Q33377109-DFA63C9F-F009-4221-84CB-512F18E38024Q33385389-2F9346D5-BE3F-4AD2-AA94-CC36724A07CAQ33602540-A6602463-2F92-4617-9255-7EB56B298D67Q33683956-AEBFC713-75B1-4E08-AF11-AA52929C4AB9Q33706447-48B86EBA-888D-4F7B-8206-B70085CE1831Q34037683-1B926307-0806-4C72-B4EC-712B7E10CF92Q34065598-F51D2A4A-BB95-4967-84E9-E769B15EBED3Q34075484-6182171C-497C-4151-B81C-AD0B740A6DF3Q34087859-80AABEB3-C82C-4C41-936A-CAD271DE0A50Q34156332-573901D8-52B4-46E3-9A91-255F14B59A76Q34176634-C60A4787-FB8D-4769-A7E8-D4C4968339E0Q34244998-0FDA9391-79A8-4B0F-9080-40605566CD57Q34282077-918EF461-C454-426D-9E60-317F5479F993Q34687563-85548903-0EF4-4157-A1BD-2FBB62DAFC22Q34974448-9F550893-5D3E-4184-A1DF-A88DF2755EE1Q35029858-7ED4C22E-879A-4F82-A937-CB60548A09BEQ35065425-0A977807-97D5-4ECF-B179-A1F61F49C3C2Q35109118-F3C2912E-164A-40B7-8755-99912DE64B98Q35548589-A8D4DD43-0029-4FA8-80D3-16B86F779A8CQ35557092-DAD0C47F-2344-4BEB-A956-C238F2273645Q35557832-244A4813-7D65-4DF5-9ACC-AB6E685BF95FQ35606909-C4EC6C9A-6736-469F-9AAD-0D7B0CE6AFB9Q35759939-ADE45C07-49FC-4F1A-9B62-86D885C055EFQ35760171-19699ADB-CC55-4FB5-9F6C-49F92EE3A31BQ35777619-0AA7CD68-B55F-46A4-BB16-C0DB61FE0B8BQ35887318-84AD94E4-AAA6-4E86-A94F-8C845D806429Q35953330-A2F92CA4-8FD3-445D-A41E-E0582E1C9BA4Q36171750-D438A548-04EF-45CF-913A-ED235E1F5923Q36354929-7BA0C554-2C75-4CED-A14F-D76DE69AF9A0Q36504479-9A615E6E-8CE7-44AB-854E-D74403828306Q36684589-E7E6A86C-D37A-420B-85A4-6B3F4F4D31F2Q36706610-1A02349F-5BF9-4331-A35E-CB90E8CA4DA5Q36769703-8B73AD53-28DC-4AFE-89FB-05830B5A3CC4Q36802625-BB3BCADB-C86B-4D77-94A4-D7A77ACC39DDQ36860837-12751BC3-9D52-4427-BCEA-1B41EA3D5CCAQ36878215-AA3FD7DA-ADCE-4E5A-A7A9-F87585CB3E97Q36897408-3B8FC7C1-F21A-4B0D-AF93-7DBD3CE7891F
P2860
Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 October 2005
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Rituximab for refractory Wegen ...... ective, open-label pilot trial
@en
Rituximab for refractory Wegen ...... ctive, open-label pilot trial.
@nl
type
label
Rituximab for refractory Wegen ...... ective, open-label pilot trial
@en
Rituximab for refractory Wegen ...... ctive, open-label pilot trial.
@nl
prefLabel
Rituximab for refractory Wegen ...... ective, open-label pilot trial
@en
Rituximab for refractory Wegen ...... ctive, open-label pilot trial.
@nl
P2093
P2860
P1476
Rituximab for refractory Wegen ...... ective, open-label pilot trial
@en
P2093
Darrell R Schroeder
Fernando C Fervenza
Karina A Keogh
Kimberly A Carlson
Steven R Ytterberg
Ulrich Specks
P2860
P304
P356
10.1164/RCCM.200507-1144OC
P407
P577
2005-10-13T00:00:00Z